These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 15642164)
1. Letrozole sensitizes breast cancer cells to ionizing radiation. Azria D; Larbouret C; Cunat S; Ozsahin M; Gourgou S; Martineau P; Evans DB; Romieu G; Pujol P; Pèlegrin A Breast Cancer Res; 2005; 7(1):R156-63. PubMed ID: 15642164 [TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851 [TBL] [Abstract][Full Text] [Related]
3. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175 [TBL] [Abstract][Full Text] [Related]
4. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
5. Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment. Zeng ZJ; Li JH; Zhang YJ; Zhao ST Cancer Radiother; 2013 Jun; 17(3):208-14. PubMed ID: 23664221 [TBL] [Abstract][Full Text] [Related]
6. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381 [TBL] [Abstract][Full Text] [Related]
7. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674 [TBL] [Abstract][Full Text] [Related]
8. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? Kaufmann M; Rody A Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229 [TBL] [Abstract][Full Text] [Related]
9. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Azria D; Belkacemi Y; Romieu G; Gourgou S; Gutowski M; Zaman K; Moscardo CL; Lemanski C; Coelho M; Rosenstein B; Fenoglietto P; Crompton NE; Ozsahin M Lancet Oncol; 2010 Mar; 11(3):258-65. PubMed ID: 20138810 [TBL] [Abstract][Full Text] [Related]
10. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. Monnier AM Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927 [TBL] [Abstract][Full Text] [Related]
11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Berry J Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441 [TBL] [Abstract][Full Text] [Related]
12. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Liu XH; Zheng XF; Wang YL Chin Med J (Engl); 2009 Jul; 122(14):1681-5. PubMed ID: 19719971 [TBL] [Abstract][Full Text] [Related]
13. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
14. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Sonne-Hansen K; Lykkesfeldt AE J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829 [TBL] [Abstract][Full Text] [Related]
15. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415 [TBL] [Abstract][Full Text] [Related]
16. Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). Han M; Kim JY; Park JE; Kim JM; Lee KS Eur J Obstet Gynecol Reprod Biol; 2008 May; 138(1):83-8. PubMed ID: 18164802 [TBL] [Abstract][Full Text] [Related]
17. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Lane HA; Lebwohl D Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231 [TBL] [Abstract][Full Text] [Related]
19. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Cao W; Yacoub S; Shiverick KT; Namiki K; Sakai Y; Porvasnik S; Urbanek C; Rosser CJ Prostate; 2008 Aug; 68(11):1223-31. PubMed ID: 18465755 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]